ATE365808T1 - Transportproteine und deren verwendungen - Google Patents

Transportproteine und deren verwendungen

Info

Publication number
ATE365808T1
ATE365808T1 AT96925874T AT96925874T ATE365808T1 AT E365808 T1 ATE365808 T1 AT E365808T1 AT 96925874 T AT96925874 T AT 96925874T AT 96925874 T AT96925874 T AT 96925874T AT E365808 T1 ATE365808 T1 AT E365808T1
Authority
AT
Austria
Prior art keywords
transport proteins
proteins
cells
methods
transport
Prior art date
Application number
AT96925874T
Other languages
English (en)
Inventor
Peter Francis Joseph O'hare
Gillian Daphne Elliott
Original Assignee
Marie Curie Cancer Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515568.5A external-priority patent/GB9515568D0/en
Priority claimed from GBGB9601570.6A external-priority patent/GB9601570D0/en
Application filed by Marie Curie Cancer Care filed Critical Marie Curie Cancer Care
Application granted granted Critical
Publication of ATE365808T1 publication Critical patent/ATE365808T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96925874T 1995-07-28 1996-07-25 Transportproteine und deren verwendungen ATE365808T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515568.5A GB9515568D0 (en) 1995-07-28 1995-07-28 Transport proteins and their uses
GBGB9601570.6A GB9601570D0 (en) 1996-01-26 1996-01-26 Transport proteins and their uses

Publications (1)

Publication Number Publication Date
ATE365808T1 true ATE365808T1 (de) 2007-07-15

Family

ID=26307479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925874T ATE365808T1 (de) 1995-07-28 1996-07-25 Transportproteine und deren verwendungen

Country Status (11)

Country Link
US (4) US6184038B1 (de)
EP (1) EP0845043B1 (de)
JP (1) JPH11510386A (de)
CN (1) CN1208438A (de)
AT (1) ATE365808T1 (de)
AU (1) AU705563B2 (de)
BR (1) BR9610058A (de)
CA (1) CA2227786A1 (de)
DE (1) DE69637147T2 (de)
MX (1) MX9800719A (de)
WO (1) WO1997005265A1 (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0845043B1 (de) * 1995-07-28 2007-06-27 Marie Curie Cancer Care Transportproteine und deren verwendungen
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
GB9705903D0 (en) * 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
WO1998055145A1 (en) * 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
CA2319437C (en) 1998-01-31 2009-06-16 University Of Arkansas Methods and reagents for decreasing allergic reactions
GB9816761D0 (en) 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
DE19845420C2 (de) * 1998-10-02 2000-11-16 Deutsches Krebsforsch Interzelluläre Ausbreitung rekombinanter DNA
PT1129064E (pt) * 1998-11-12 2008-01-31 Invitrogen Corp Reagentes de transfecção
US6316252B1 (en) * 1998-12-17 2001-11-13 Wisconsin Alumni Research Foundation Biotherapeutic delivery system
DE60040274D1 (de) * 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
JP2002539839A (ja) * 1999-03-31 2002-11-26 インヴィトロゲン・コーポレーション 転位ポリペプチドによる機能性タンパク質配列の送達
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
ATE342275T1 (de) * 1999-04-12 2006-11-15 Heart Biosystems Gmbh Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
DE19933089A1 (de) * 1999-07-15 2001-01-18 Max Delbrueck Centrum Mittel zur Gewerbsregeneration
WO2001015511A2 (en) 1999-09-01 2001-03-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
US20030219826A1 (en) * 1999-09-01 2003-11-27 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
ATE345389T1 (de) 1999-09-30 2006-12-15 Univ Washington Immunologisch relevante antigene aus herpes simplexvirus
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE19955576B4 (de) * 1999-11-18 2008-02-28 Faustus Forschungs Cie. Translational Cancer Research Gmbh Transferverbindungen, ihre Herstellung und ihre Verwendung
GB9930519D0 (en) 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
DE10001230A1 (de) * 2000-01-13 2001-08-02 Deutsches Krebsforsch Immunisierungsmittel
US6688084B2 (en) * 2000-03-24 2004-02-10 International Paper Company Automated bulk box strapper
US7318928B2 (en) * 2000-08-01 2008-01-15 The Johns Hopkins University Molecular vaccine linking intercellular spreading protein to an antigen
GB0022101D0 (en) * 2000-09-08 2000-10-25 Phogen Ltd Delivery of substances to cells
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP2191845A1 (de) 2001-07-31 2010-06-02 University of Washington Immunologisch bedeutende Herpes-simplex-virus-antigene und Verfahren für ihre Verwendung
WO2003042239A1 (en) * 2001-11-12 2003-05-22 Stichting Sanquin Bloedvoorziening Peptides inhibiting signaling by ras-like gtpases
WO2004015061A2 (en) * 2002-05-17 2004-02-19 Automated Cell, Inc. Determination of protein function
AU2003254089A1 (en) * 2002-07-19 2004-02-09 Myriad Genetics, Inc Method and composition for treating and preventing herpesvirus infection
AU2003267124A1 (en) 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
IL157787A (en) * 2003-09-07 2010-12-30 Mosaid Technologies Inc Modular outlet for data communications network
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
GB0321311D0 (en) * 2003-09-12 2003-10-15 Phogen Ltd Delivery of substances to cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP1920248B1 (de) 2005-04-05 2010-09-29 Allergan, Inc. Clostridientoxinaktivitätstests
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
CN103773804A (zh) 2005-12-13 2014-05-07 国立大学法人京都大学 核重新编程因子
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101374860A (zh) 2005-12-23 2009-02-25 技术转让合伙人公司 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
GB0724253D0 (en) * 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
CN101855350B (zh) 2008-05-02 2014-12-31 国立大学法人京都大学 核重编程序方法
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (de) 2009-04-03 2013-05-01 Univ Washington Antigenes hsv-2-peptid und verwendungsverfahren dafür
GB0917792D0 (en) * 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
AU2010348409B2 (en) 2010-03-18 2014-03-20 Spiber Technologies Ab Production of proteins and polypeptides
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012006440A2 (en) 2010-07-07 2012-01-12 Cellular Dynamics International, Inc. Endothelial cell production by programming
ES2688030T3 (es) 2010-10-14 2018-10-30 Xigen Inflammation Ltd. Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9127283B2 (en) 2010-11-24 2015-09-08 Clontech Laboratories, Inc. Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
CN104023736A (zh) 2011-11-30 2014-09-03 埃克西金炎症有限公司 Jnk信号转导途径的细胞-可渗透肽抑制剂用于治疗干眼综合征的用途
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (de) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Von kardiosphären abgeleitete exosomen zur geweberegeneration
AU2013317985B2 (en) 2012-09-19 2019-06-13 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
WO2015197098A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3204031A2 (de) 2014-10-08 2017-08-16 Xigen Inflammation Ltd. Verwendung von zelldurchlässigen peptidhemmern des jnk-signaltransduktionsweges zur behandlung verschiedener krankheiten
KR20180018507A (ko) 2015-04-20 2018-02-21 톨레로 파마수티컬스, 인크. 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측
JP6814745B2 (ja) 2015-04-27 2021-01-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法
DK3298021T3 (da) 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc Alvocidib-prodrugs, der har øget biotilgængelighed
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
EP3402543B1 (de) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Aus kardiosphäre stammende zellen und durch solche zellen sekretierte exosomen in der behandlung von herzversagen mit konservierter auswurffraktion
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP6619519B2 (ja) 2016-12-19 2019-12-11 トレロ ファーマシューティカルズ， インコーポレイテッド プロファイリングペプチドおよび感受性プロファイリングのための方法
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (de) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center Verfahren zur therapeutischen verwendung von exosomen und y-rnas
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020176689A1 (en) 2019-02-26 2020-09-03 Dana-Farber Cancer Institute, Inc. Live cell imaging dynamic bh3 profiling
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312681B1 (no) 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6251395B1 (en) * 1993-12-23 2001-06-26 W. Michael Gallatin Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
FR2736915B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Rorer Sa Variants de la proteine p53 et utilisations therapeutiques
EP0845043B1 (de) * 1995-07-28 2007-06-27 Marie Curie Cancer Care Transportproteine und deren verwendungen
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses

Also Published As

Publication number Publication date
EP0845043B1 (de) 2007-06-27
US20030219859A1 (en) 2003-11-27
CA2227786A1 (en) 1997-02-13
US6184038B1 (en) 2001-02-06
DE69637147T2 (de) 2008-03-06
CN1208438A (zh) 1999-02-17
BR9610058A (pt) 1999-07-27
US6521455B2 (en) 2003-02-18
DE69637147D1 (de) 2007-08-09
AU6623996A (en) 1997-02-26
EP0845043A1 (de) 1998-06-03
JPH11510386A (ja) 1999-09-14
WO1997005265A1 (en) 1997-02-13
MX9800719A (es) 1998-11-29
AU705563B2 (en) 1999-05-27
US20020039765A1 (en) 2002-04-04
US20060051869A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
ATE365808T1 (de) Transportproteine und deren verwendungen
BR9610511B1 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
BRPI9811940A (pt) vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada.
ATE402254T1 (de) Aav5 vektoren und deren verwendung
DE69837613D1 (de) J-kette und analoge für konjugate zielgerichtet auf epithelzellen
ATE302217T1 (de) Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
TR199501134A2 (tr) Memeli ve viral proteinleri asiri ifade edilmesi.
DE69935248D1 (de) Dna-protein fusionen sowie anwendungen derselben
ATE242323T1 (de) Transportprotein, das den transport von kationischen xenobiotika und/oder pharmaka bewirkt, dafür kodierende dna-sequenzen und deren verwendung
ATE293700T1 (de) Adenovirus mit glutathion peroxydate gene
ATE273388T1 (de) Veränderte menschliche c3-proteine
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
BR0014758A (pt) Sistemas e métodos para expressão de proteìna com alto rendimento
AU3677095A (en) Radioactive phosphorous labeling of proteins for targeted radiotherapy
TR200102985T2 (tr) Gen tedavisi teknikleri.
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
ATE247978T1 (de) Verwendung von ompa enterobakterproteinen um zielgerichtet antigen-präsentierende zellen anzusteuern
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
BR9909044A (pt) Vetor de tranferência de ácidos nucleicos, composição, utilização de um vetor de tranferência de ácidos nucleicos, processos de transfecção de ácidos nucleicos nas células, e de tratamento de doenças, e, célula recombinante
GB9723825D0 (en) Nuclear targeting by means of bacterial proteins
BR9507507A (pt) Polipeptideo proteina para uso como uma toxina sequéncia de nucleotídeos processo para produzir um polipeptideo molécula de dna recombinante vetor de express o célula inseticida sistema inseticida planta animal n o humano toxina processo para produzir um polipeptídeo ativo de um polipeptídeo precursor inativo isolado sequéncia base de nucleotídeos isolada sequéncia base siolada nova toxina poliptídeo isolado e novo assunto ou combinaç o
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
RU95111293A (ru) Способ терапии острой пневмонии
ATE266418T1 (de) Malignitätsunterdrückung durch verwendung von ribonucleotid reductase r1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties